Join

Compare · DXCM vs SILK

DXCM vs SILK

Side-by-side comparison of DexCom Inc. (DXCM) and Silk Road Medical Inc. (SILK): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both DXCM and SILK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • DXCM is the larger of the two at $29.57B, about 27.8x SILK ($1.07B).
  • DXCM has hit the wire 26 times in the past 4 weeks while SILK has been quiet.
  • Both have 25 recent analyst ratings on file.
MetricDXCMSILK
Company
DexCom Inc.
Silk Road Medical Inc.
Price
$76.59+5.15%
$27.50+0.02%
Market cap
$29.57B
$1.07B
1M return
+25.71%
-
1Y return
-10.56%
-
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NASDAQ
NASDAQ
IPO
2005
2019
News (4w)
26
0
Recent ratings
25
25
DXCM

DexCom Inc.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

SILK

Silk Road Medical Inc.

Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products includes ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.

Latest DXCM

Latest SILK